What smart money is saying about Avidity Biosciences
RNA
No fund has written a full thesis on Avidity Biosciences in our archive, but 2 fund letters report a position in it — most recently Clearbridge Small Cap Growth Strategy in December 2025.
Get an email when a fund writes about it
2
Reported positions
1
Bought
1
Sold
2
Letters
Position history
Between Q3 2025 and Q4 2025, 2 fund letters reported a position in Avidity Biosciences — 1 opened or added to the position, 1 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q4 2025 | 1 | 0 | 1 | 0 |
| Q3 2025 | 1 | 1 | 0 | 0 |
Fund activity · 2 positions · 2 moves
- December 2025
“We also exited six positions: Avidity Biosciences (which was acquired by Novartis), Installed Building Products, Glaukos, Biohaven, Qualys and Duolingo.”
Avidity Biosciences - New positionClearbridge Small Cap StrategySeptember 2025
“We also established a new position in Avidity Biosciences, a development-stage biotechnology company with a proprietary platform for delivering RNA-based therapeutics to muscle tissue.”
Avidity Biosciences
Read the letters behind these Avidity Biosciences positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger